Pharma BD Deal Intelligence
Low-cost entry to a validated complement target; execution- and tolerability-gated
Full analysis, sources & comparables →Mirador Therapeutics enters an exclusive worldwide license to KP-301, a long-acting anti-C5a antibody with potential in ANCA-associated vasculitis; Phase…
Mirador unveils part of its pipeline with KP-301, licensed from Kira, positioned to rival the troubled AAV drug Tavneos (avacopan); $12M upfront plus…
Kira out-licenses KP-301 (anti-C5a mAb) and KP-402 (C5a receptor antagonist) to Mirador Therapeutics for $12M upfront plus development and sales milestones.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Mirador Therapeutics entered an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small-molecule C5a receptor antagonist, announced July 16, 2026 alongside Kira's acquisition by Jasper Therapeutics. Mirador pays $12 million upfront plus undisclosed development and sales milestones. KP-301 is targeted at ANCA-associated vasculitis, with a Phase 1 study planned by year-end 2026 and a Phase 2 AAV study in H1 2027, with potential expansion into additional inflammatory indications.
ANCA-associated vasculitis (AAV) is a group of serious autoimmune diseases - granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) - characterized by inflammation and destruction of small blood vessels, frequently causing kidney and lung damage. A 20-year U.S. population-based study estimated prevalence of ~42 per 100,000 and annual incidence of ~3.3 per 100,000 (global estimates 200-400 per million). The complement C5a/C5aR axis is a validated driver of neutrophil-mediated vascular injury in AAV, the target the approved oral agent avacopan (Tavneos) exploits, but substantial unmet need persists for better-tolerated, steroid-sparing options.
The approved comparator is Tavneos (avacopan, Amgen/ChemoCentryx), an ORAL small-molecule C5a RECEPTOR (C5aR1) antagonist approved for AAV in 2021; standard of care is rituximab (anti-CD20 monoclonal antibody) or cyclophosphamide plus glucocorticoids. KP-301 differentiates as a long-acting anti-C5a antibody that neutralizes the C5a LIGAND upstream of the receptor, engineered via pH-dependent binding and antibody recycling for durable coverage at low, infrequent dosing - positioned to improve on avacopan's twice-daily oral burden and on the safety/steroid-sparing profile clinicians still seek. KP-402, a small-molecule C5aR antagonist, gives Mirador a second, oral shot on the same axis as avacopan.
Concurrent with Jasper's acquisition of Kira, Mirador Therapeutics obtains an exclusive worldwide license to KP-301 (long-acting anti-C5a mAb) and KP-402 (small-molecule C5aR antagonist), paying $12 million upfront plus undisclosed development and sales milestones, expanding its precision immunology portfolio (Mirador360 platform) into complement-mediated disease.
Mirador plans to initiate a Phase 1 study of KP-301 by the end of 2026 (projected milestone; not yet started).
A Phase 2 study of KP-301 in AAV is planned for the first half of 2027, with potential expansion into additional inflammatory indications (projected milestone).
At just $12M upfront, Mirador acquires a differentiated long-acting anti-C5a antibody plus a backup oral C5aR antagonist on a clinically validated axis. Upside depends on KP-301 delivering durable, low-frequency dosing and a cleaner safety/steroid-sparing profile than the approved oral agent avacopan - but both assets are still preclinical, so returns are early and milestone-gated.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mirador Therapeutics, Inc. / Kira Pharmaceuticals (this deal) | 2026 | $12M | 56 |
| Arcturus Therapeutics, Inc. / CSL Seqirus (CSL Limited) | 2026 | $28M | 100 |
| Genentech, Inc. (Roche Group) / Duality Biologics (Suzhou) Co. Ltd. | 2026 | $1.0B | 100 |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2026 | $2.3B | 100 |
| Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. | 2026 | $2.5B | 75 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
| AstraZeneca PLC / Dizal Pharmaceutical Co., Ltd | 2026 | $1.5B | 73 |
← Browse all deals · How we score deals
More: 2026 deals